Treatment with IFNβ reversed this reduced suppressive effect as CD4+ memory T-cells of IFNβ-treated MS patients showed a comparable suppressive activity to healthy controls (Fig 6a). This evidence concerns the gene IFNB1 and myeloid sarcoma.